Abstract
Although a wide range of therapeutic options are available for relapsing–remitting multiple sclerosis (MS), the therapeutic landscape for progressive forms of the disease is highly unsatisfactory. Therefore, the identification of effective therapies for progressive MS (PMS) is a highly relevant challenge for the global MS medical community. To achieve this, a better understanding of the mechanisms involved in PMS is required through novel clinical trial designs, new drug repurposing strategies and new methods of collaboration in identifying effective therapies. In this review, we discuss the first compounds already available for PMS as well as other therapies currently undergoing phase II and III clinical trials.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
